Consolidated income statement For the year ended 31 March 2017 2017 2016 Restated Before Other Before Other other items items Total other items items Total Notes m m m m m m Continuing operations Revenue 3,4 2,126.3 2,126.3 2,146.9 2,146.9 Cost of sales 1,896.5 1,896.5 1,849.8 1,849.8 Gross profit 229.8 229.8 297.1 297.1 Administrative expenses 236.7 36.6 273.3 183.8 6.3 190.1 Share of profit of joint ventures and associates 17 0.6 0.6 0.6 0.6 Operating loss profit 4,7 6.3 36.6 42.9 113.9 6.3 107.6 Investment revenue 9 0.1 0.1 Finance costs 10 15.3 15.3 15.8 15.8 Net finance costs 15.3 15.3 15.7 15.7 Loss profit before tax 21.6 36.6 58.2 98.2 6.3 91.9 Tax 11 3.3 4.1 7.4 19.5 1.3 18.2 Loss profit from continuing operations after tax 18.3 32.5 50.8 78.7 5.0 73.7 Discontinued operations Loss from discontinued operations 6 11.4 121.0 132.4 5.0 34.0 39.0 Loss profit for the year 4 29.7 153.5 183.2 73.7 39.0 34.7 Attributable to: Equity holders of the parent 30.5 153.5 184.0 71.6 39.0 32.6 Non-controlling interests 0.8 0.8 2.1 2.1 29.7 153.5 183.2 73.7 39.0 34.7 Loss earnings per share EPS attributable to equity shareholders of the parent From continuing operations: basic 13 5.5 p 9.2 p 14.7 p 21.6p 1.5 p 20.1p diluted 13 5.4 p 9.2 p 14.6 p 21.3p 1.4 p 19.9p From continuing and discontinued operations: basic 13 8.7 p 43.7 p 52.4 p 20.1p 10.9 p 9.2p diluted 13 8.6 p 43.3 p 51.9 p 19.9p 10.8 p 9.1p See Note 1 c for an explanation and analysis of the prior year restatements included above in respect of the year ended 31 March 2016.
See Note 6 for further detail on the re-presentation of the prior year comparatives due to the treatment of the Healthcare business as a discontinued operation.
Other items are as described in Note 5. www.
